ʻO Semaglutude he Glucose-hoʻemiʻana i ka lāʻau lapaʻau i hoʻomohalaʻia e Novisk no ka mālamaʻana i nā maʻi maʻi 2. I Iune 2021,ʻo ka FDA iʻaeʻiaʻo FDA iʻaeʻia no ka kūʻaiʻana ma ke kūʻaiʻana ma keʻano he momona momona ʻO ka lāʻau lapaʻau kahi glucagon-like peptide 1 (glp-1) ke loaʻaʻana o ka momona, ae hōʻemi i ka pōloli, no laila ua kūpono hoʻi i ka makeʻaiʻana.
Ma ka hoʻohanaʻiaʻana e hana i ka maʻi "maʻi maʻi no ka maʻi a me ka hanu, ua loaʻa ka semagelutie i ka olakino cardiovascular, e hōʻemi i ka maʻi kolohe. Eia kekahi, ua hōʻikeʻia nā haʻawina houʻelua e hiki ke hōʻemi i ka maʻi o ka maʻi o ka maʻiʻeha a me ka maʻi alzheimer.
Ua hōʻike mua nā haʻawina ma mua ua hiki i ka nalowale kaumaha ke hōʻoluʻolu i nā hōʻailona o nā kuli osteoarthritis (me keʻano o kaʻehaʻeha Eia nō naʻe,ʻo nā hopena o ka GLP-1 Loaʻa i ka momona o nā lāʻau lapaʻau e like me ka semaglute ma nā hopena o nā kuli
MaʻOkakopa 30, 2024, nā mea noiʻi mai ke kulanui o Copenhagen i paʻiʻia i kaʻoihana noiʻi hou o ka lāʻau lapaʻau.
Ua hōʻikeʻia kēia noiʻi hoʻokele e hiki ke hōʻemi nui i ke kaumaha a hōʻemi nui i kaʻeha e pili ana i ka opitio) ʻO kēia ka manawa mua, heʻano hou o ke kaumaha o ke kaumaha
Post Time: Feb-27-2025